|Year : 2015 | Volume
| Issue : 4 | Page : 389-392
Primary parietal myeloid sarcoma
Laxminadh Sivaraju1, Dilip Mohan1, Nandita Ghosal2, Bevinahalli N Nandeesh3, Alangar S Hegde1
1 Department of Neurosurgery, Sri Sathya Sai Institute of Higher Medical Sciences, Bengaluru, Karnataka, India
2 Department of Pathology, Sri Sathya Sai Institute of Higher Medical Sciences, Bengaluru, Karnataka, India
3 Department of Neuropathology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
|Date of Web Publication||20-Jan-2016|
Department of Neurosurgery, Sri Sathya Sai Institute of Higher Medical Sciences, Whitefield, Bengaluru - 560 066, Karnataka
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Intracranial occurrence of myeloid sarcoma without any evidence of systemic hematological disorder is uncommon. We report the case of a 17-year-old girl who presented with features of raised intracranial pressure and paraparesis of short duration. Magnetic resonance imaging showed a 6 cm bilateral middle 1/3rd para sagittal contrast enhancing extra-axial mass with mass effect. The tumor was subtotally excised. Histology and immunohistochemistry proved to be a myelosarcoma. Further evaluation done with peripheral blood smear and bone marrow biopsy ruled out the possibility of leukemia or myeloproliferative disorder. She was referred for chemotherapy and clinically showed improvement after 6 months of follow-up. Authors report a case of intracranial myelosarcoma which closely resembled meningioma both radiologically and in intraoperative morphological appearance. Authors discuss in detail the radiological and histological features of myelosarcoma along with differential diagnoses and treatment options.
Keywords: Immunohistochemistry, intracranial, myeloid sarcoma, parietal
|How to cite this article:|
Sivaraju L, Mohan D, Ghosal N, Nandeesh BN, Hegde AS. Primary parietal myeloid sarcoma. J Pediatr Neurosci 2015;10:389-92
| Introduction|| |
Myeloid sarcomas (MS) or granulocytic sarcomas have been associated with acute myelogenous leukemia, myelodysplastic, or myeloproliferative disorder., Uncommonly, they can occur alone without peripheral blood or bone marrow (BM) evidence of leukemia. MS is a neoplasm of immature granulocytes, monocytes, or both involving any extra-medullary site. It can develop before, simultaneously or after the onset of systemic leukemia.
| Case Report|| |
A 17-year-old female presented with complaints of headache and blurred vision in both eyes for 1 month. She also had history of bilateral lower limb weakness more on left side for 1 month and multiple episodes of generalized seizures for 20 days. On examination she could count fingers close to the face bilaterally with fundi showing papilledema in both eyes. She had Grade 5 power in both upper limbs, Grade 3 power in the right and Grade 1 in the left lower limb respectively. Her magnetic resonance imaging (MRI) showed a 5.9 cm × 4.6 cm × 2.7 cm bilateral middle 1/3rd para sagittal extra-axial mass. It was isointense in both T1- and T2-weighted images. It showed mass effect, perilesional edema, and contrast enhancement along the falx. The tumor showed restriction in the diffusion-weighted images and increased perfusion in the perfusion-weighted images. MR venogram showed blockage in middle of the superior sagittal sinus due to tumor invasion. Spectroscopy showed high choline peak suggesting increased cell turnover [Figure 1]. Meningioma and hemangiopericytoma were considered as the main differential diagnoses on radiology. She underwent bi-parietal parasagittal craniotomy and subtotal excision leaving the tumor within the sinus. Intraoperatively dura was thickened. Tumor had attachment to convexity as well as the falx. It was firm, grayish, and moderately vascular. There was no infiltration of bone by the tumor and the bone flap was replaced back. There was no definite arachnoid plane with the surrounding normal brain. Postoperative MR showed residual tumor along and within the sinus. Postoperative period was uneventful and there was mild improvement in her weakness in both lower limbs. Tumor was sent for histopathological examination.
|Figure 1: (a) Tumor was isointense in T2-weighted images.(b) Coronal and. (c) sagittal images showed contrast enhancement. (d) Magnetic resonance venogram showed the blockage of superior sagittal sinus in the middle. (e) Increased perfusion was seen in the perfusion-weighted image sequence. (f) The spectroscopy showed high choline peak. (g) Coronal and. (h) sagittal postoperative contrast images showed residual tumor within the sinus|
Click here to view
On histopathology tumor was composed of sheets of round to oval cells with vesicular nuclei, nuclear indentation in many and scant to moderate faint eosinophilic cytoplasm. In addition, few eosinophils, neutrophils and lymphocytes were seen admixed with the tumor cells. Prominent apoptotic bodies with mitotic activity were noted. Immunohistochemistry showed strong and diffuse positivity for myeloperoxidase (MPO), whereas CD34 was focally positive and tumor was negative for epithelial membrane antigen, leucocyte common antigen, CD99, CD20, CD3 and desmin [Figure 2] and [Figure 3]. Overall features were consistent with myeloid sarcoma. No fresh sample was available for fluorescence in situ hydridization or cytogenetics studies.
|Figure 2: (a-c) Microphotograph showing a polymorphous infiltrate with many immature round cells (a: H and E, ×100, b: H and E, ×200, c: H and E, ×200). (d) Tumor cells positive for myeloperoxidase immunohistochemistry (×400)|
Click here to view
|Figure 3: Paraffin section of chloroma showing (a) round to oval cells with eosinophilic cytoplasm, nuclear indentation and maturation into neutrophils with (b) focal immunopositivity for CD34 (a: H and E, ×400, b: Avidin biotin complex immunoperoxidase, ×400)|
Click here to view
Further workup done to evaluate systemic disease showed no evidence to support it. Her BM biopsy and peripheral blood smear tests were normal. There was no evidence of systemic leukemic disorder. She was advised to take chemotherapy. Patient was put on cyclophosphamide based chemotherapy and remained asymptomatic after 6 months of follow-up.
| Discussion|| |
Myeloid sarcoma is also called as chloroma due to its greenish hue resulting from the presence of myeloperioxidase. In the cranial cavity, the MS is postulated to emerge from the BM of the skull. It then traverses the haversian canals, spreads up to the subperiosteum, breaches the dura and manifests as an extra-axial lesion occupying the subarachnoid space. The tumor may penetrate the pia, invade the parenchyma and present as an intra-axial mass. Intracranial myeloid sarcomas have been reported in both infra- and supra-tentorial locations. The WHO described myeloid sarcoma as a tumour comprising of myeloid blasts with or without maturation occurring at an anatomical site other than the BM.
Radiologically the tumor is hypointense to isointense on both T1-weighted and T2-weighted images in relation to gray matter with marked homogeneous enhancement following contrast administration. The signal intensity of the tumor on the T2-weighted images was due to high levels of MPO, an iron-containing enzyme normally found in white blood cells., Identification of tumor involvement in BM has also been reported on MRI, and this finding may suggest the diagnosis of a myeloid sarcoma.
Even though the tumor can occur in any part of the body - skin, lymph node, gastrointestinal tract and testis are more frequently involved. In less than 10% of cases it may occur in multiple anatomical sites. A myeloid sarcoma is most commonly composed of myeloblasts with or without features of neutrophilic maturation., On immunohistochemistry CD68/KP1 is the most commonly expressed marker, followed by MPO, CD117, CD68/PG-M1, lysozyme, and CD34. MS was classified into five types based on morphological and immunohistochemical analyses. The five types are (a) immature granulocytic sarcoma, (b) differentiated granulocytic sarcoma, (c) monoblastic sarcoma, (d) monocytic sarcoma, and (e) myelomonocytic sarcoma. The chromosomal abnormalities detected were monosomy 7, trisomy 8, trisomy 4, and monosomy 16.
The main differential diagnosis to be considered is malignant lymphoma. MS share morphological features similar to non-Hodgkins lymphoma and both express certain markers, such as CD43 and CD45. An inadequate workup may lead to confounding diagnosis. The diagnosis of myeloid sarcoma is confirmed by the results of cytochemical and immunophenotypic analyses. These aid the diagnosis of myeloid sarcoma and differentiate it from the lymphoblastic lymphoma, Burkitt lymphoma and diffuse large B-cell lymphoma. In our study, B-cell and T-cell lymphomas were excluded by negative stains for CD20, and CD3, respectively. Negative staining for desmin ruled out the possibility of rhabdomyosarcoma and CD99 negativity ruled out Ewings sarcoma.
The current recommended treatment for patients with isolated MS is the same conventional acute myeloid leukemia (AML) chemotherapeutic protocol. Cytarabine has been found as a key drug in the regimen. There is no evidence at present that adding radiotherapy has positive effect on the survival compared to chemotherapy alone. There is no concrete evidence on the role of hematopoietic stem cell transplantation in patients with MS.
Few case reports of intracranial myeloid sarcoma in patients with leukemia , or spinal lesions in nonleukemic patients  are available. It is uncommon to see myeloid sarcoma presenting as an intracranial space occupying lesion without features of systemic AML. Widhalm et al. and Qian et al. presented case reports with both intracranial and intraspinal lesions. Thakar et al. presented a case of multiple skull base chloromas [Table 1]. The case reports previously described are depicted in the [Table 1] below. In addition, Pileri et al. reported 3.25% of cases of MS involving central nervous system in their series of 92 patients.
|Table 1: Published cases of primary intracranial myeloid sarcomas without progression to leukemia in the follow-up period|
Click here to view
| Conclusion|| |
Authors report primary intracranial sarcoma where the tumor radiologically and intraoperatively resembled meningioma. This case emphasize to consider MS as a differential diagnosis for extra axial mass. Tumor may not always exhibit greenish appearance or involve the bone. MS is a relatively uncommon intracranial mass lesion and the workup for secondary lesions is mandatory. These patients should be treated along the line of AML treatment protocol with chemotherapy. These patients need regular follow-up to watch for progression of the tumor to systemic leukemia, intracranial recurrences and new lesions in spine. It is also important to give adequate counselling to the patient to look for any new neurological symptoms or deficits that prompt to repeat MR brain or spine as well.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Kalayci M, Sümer M, Yenidünya S, Ozdolap S, Açikgöz B. Spinal granulocytic sarcoma (chloroma) presenting as acute cord compression in a nonleukemic patient. Neurol India 2005;53:221-3.
Alexiev BA, Wang W, Ning Y, Chumsri S, Gojo I, Rodgers WH, et al.
Myeloid sarcomas: A histologic, immunohistochemical, and cytogenetic study. Diagn Pathol 2007;2:42.
Parker K, Hardjasudarma M, McClellan RL, Fowler MR, Milner JW. MR features of an intracerebellar chloroma. AJNR Am J Neuroradiol 1996;17:1592-4.
Thakar S, Dadlani R, Ghosal N, Jethwani D, Mahadevan A, Hegde AS. Multiple intracranial de-novo
chloromas presenting with Garcin's syndrome. Clin Neuropathol 2012;31:369-73.
Nikolic B, Feigenbaum F, Abbara S, Martuza RL, Schellinger D. CT changes of an intracranial granulocytic sarcoma on short-term follow-up. AJR Am J Roentgenol 2003;180:78-80.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al
., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008. p. 140-1.
Avni B, Koren-Michowitz M. Myeloid sarcoma: Current approach and therapeutic options. Ther Adv Hematol 2011;2:309-16.
Atalay B, Altinörs N, Yilmaz C, Koçbiyik A. Extraaxial chloroma of the cerebellopontine angle: Case report. Turk Neurosurg 2007;17:286-8.
Cho WH, Choi YJ, Choi BK, Cha SH. Isolated recurrence of intracranial granulocytic sarcoma mimicking a falx meningioma in acute myeloblastic leukemia. J Korean Neurosurg Soc 2010;47:385-8.
Yoon DH, Cho KJ, Suh YL, Kim CW, Chi JG, Han DH, et al.
Intracranial granulocytic sarcoma (chloroma) in a nonleukemic patient. J Korean Med Sci 1987;2:173-8.
Widhalm G, Dietrich W, Müllauer L, Streubel B, Rabitsch W, Kotter MR, et al.
Myeloid sarcoma with multiple lesions of the central nervous system in a patient without leukemia. Case report. J Neurosurg 2006;105:916-9.
Grier DD, Al-Quran SZ, Gray B, Li Y, Braylan R. Intracranial myeloid sarcoma. Br J Haematol 2008;142:681.
Hodges G, Lai HC, Irving I, Macloud M, Korah I, Ramuz O, et al.
Isolated intracranial myeloid sarcoma. Pathology 2012;44:571-4.
Qian J, Cui QU, Liu Y, Li X, Sun X, Zhu H, et al.
Isolated primary intracranial myeloid sarcoma with neuromeningeal infiltration: A case report. Oncol Lett 2015;9:1647-50.
Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M, et al.
Myeloid sarcoma: Clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia 2007;21:340-50.
[Figure 1], [Figure 2], [Figure 3]
|This article has been cited by|
||Treatment Outcomes of Intracranial Myeloid Sarcomas: A Meta-Analysis
| ||Dennis Lee, Oluwaseun A. Omofoye, Miriam A. Nuño, Robert A. Riestenberg, Kiarash Shahlaie |
| ||World Neurosurgery. 2021; 148: 29 |
|[Pubmed] | [DOI]|